HERON THERAPEUTICS INC (HRTX)

US4277461020 - Common Stock

1.79  +0.01 (+0.56%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

HERON THERAPEUTICS INC

NASDAQ:HRTX (11/4/2024, 1:19:32 PM)

1.79

+0.01 (+0.56%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS SubIndustry
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%
Sales Q2Q%
CRS
6 Month-31.8%
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap271.49M
Shares
PEN/A
Fwd PE259.99
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

HRTX Daily chart

Company Profile

Heron Therapeutics, Inc is a biotechnology company, which engages in the development of pharmaceutical products for acute care and oncology patients. The company is headquartered in San Diego, California and currently employs 126 full-time employees. The firm commercializes a portfolio of products to care for acute care and oncology patients. Its oncology care product portfolio includes SUSTOL and CINVANTI. SUSTOL is used for the prevention of acute and delayed nausea and vomiting associated with both moderately emetogenic chemotherapy (MEC), and anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. CINVANTI is an intravenous (IV) formulation of aprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist. Its acute care product portfolio includes ZYNRELEF and APONVIE. HTX- ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. APONVIE is the IV formulation of a NK1 receptor antagonist indicated for postoperative nausea and vomiting (PONV). Its products are distributed in the United States.

Company Info

HERON THERAPEUTICS INC

4242 Campus Point Court, Suite 200

San Diego CALIFORNIA 92121

P: 18582514400

CEO: Barry Quart

Employees: 126

Website: https://www.herontx.com/

HRTX News

News Image6 days ago - Heron Therapeutics, Inc.Heron Therapeutics to Report Third Quarter 2024 Financial Results On Tuesday, November 12, 2024

/PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the Company...

News Image25 days ago - Heron Therapeutics, Inc.Heron Therapeutics Reaffirms Availability and Ample Supply of CINVANTI®, SUSTOL®, and APONVIE® as Alternatives During the Potential Shortage of Intravenous Fluids

/PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today reaffirmed the Company's...

News Imagea month ago - Heron Therapeutics, Inc.Heron Therapeutics Announces FDA Approval of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")

/PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the U.S....

News Image2 months ago - Heron Therapeutics, Inc.Heron Therapeutics Announces Appointment of Brett Fleshman as Chief Business Officer

/PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing...

News Image3 months ago - InvestorPlaceHRTX Stock Earnings: Heron Therapeutics Misses EPS, Beats Revenue for Q2 2024

HRTX stock results show that Heron Therapeutics missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.

News Image3 months ago - BusinessInsiderHRTX Stock Earnings: Heron Therapeutics Misses EPS, Beats Revenue for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Heron Therapeutics (NASDAQ:HRTX) just reported results for the second quarter o...

HRTX Twits

Here you can normally see the latest stock twits on HRTX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example